FDA Approves Combination Antibiotic Zerbaxa

Share this content:
FDA Approves Combination Antibiotic Zerbaxa
FDA Approves Combination Antibiotic Zerbaxa

TUESDAY, Dec. 23, 2014 (HealthDay News) -- The combination antibiotic Zerbaxa (ceftolozane/tazobactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated intra-abdominal infections and complicated urinary tract infections.

The approval for intra-abdominal infections is for use of Zerbaxa in combination with another drug, metronidazole, the agency said in a news release. The approval for urinary tract infection includes pyelonephritis.

Zerbaxa is the fourth antibiotic to be FDA approved in 2014, following approval of Dalvance (dalbavancin), Sivextro (tedizolid), and Orbactiv (oritavancin).

The drug's label includes a warning about decreased effectiveness among people with renal impairment, the FDA said. The most common side effects reported during clinical testing included nausea, diarrhea, headache, and pyrexia.

Zerbaxa is marketed by Cubist Pharmaceuticals, based in Lexington, Mass.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Trends in HIV/AIDS Have Worsened in African-Americans

Trends in HIV/AIDS Have Worsened in African-Americans

Action plan developed for community leaders that can reduce the disparity in HIV/AIDS

cfDNA Screening First for Trisomy 21 Doesn't Cut Miscarriage Rate

cfDNA Screening First for Trisomy 21 Doesn't Cut ...

Invasive testing if positive for trisomy 21 on cfDNA screen compared with immediate invasive testing

HPV Legislation Doesn't Impact Teen Sexual Behaviors

HPV Legislation Doesn't Impact Teen Sexual Behaviors

No substantive or significant associations between HPV legislation and adolescent sexual behaviors

is free, fast, and customized just for you!




Already a member?

Sign In Now »